FASTER FUSION. PROVEN PERFORMANCE.

InQu® is the cell-friendly biosynthetic™ bone graft with proven clinical efficacy leading to faster bone fusion.
InQu Bone Graft Extender & Substitute combines a biologic molecule with the consistency and cost-effectiveness of a synthetic to create a new category of bone graft: **Biosynthetic.**

**IN A CLASS OF ITS OWN**
Discover the benefits of a biosynthetic and achieve better patient outcomes with InQu.

- **Proven Efficacy**
  Clinically proven fusion rates of 94%, outperforming fusion rates for ICBG at 12 months¹.

- **Faster Fusion**
  Shorter time to fusion vs. traditional synthetic bone grafts AND superior overall fusion rates at 12 months: 93% vs. 68%⁴.

- **Use with Confidence**
  InQu offers a cost-effective, on-label solution for fusion throughout the spine.

- **Cell-Friendly**
  Integrated hyaluronic acid creates a cell-friendly microenvironment, binding MSCs and growth factors²,³.

- **Success in Complex Cases**
  Demonstrated robust fusion, even in challenging high-risk patients.

- **Exceptional Handling**
  A cohesive, moldable putty providing ease-of-use for a variety of applications.
A comparative study of InQu vs. β-TCP in PLF shows InQu promoted a higher rate of fusion at 12 months (92.9% InQu vs. 67.9% β-TCP) and was almost 4 months faster to fuse than β-TCP (206 vs. 318 days). Outperforms ICBG. In a study of 109 single and multilevel PLIF spinal procedures, InQu demonstrated solid fusion in 94% of levels treated at 12 months. Mean time to fusion was 10 months.

Faster Fusion than β-TCP

Outperforms ICBG

Efficacy in Broad Application

<table>
<thead>
<tr>
<th>Faster Fusion than β-TCP</th>
<th>Outperforms ICBG</th>
<th>Efficacy in Broad Application</th>
</tr>
</thead>
<tbody>
<tr>
<td>A comparative study of InQu vs. β-TCP in PLF shows InQu promoted a higher rate of fusion at 12 months (92.9% InQu vs. 67.9% β-TCP) and was almost 4 months faster to fuse than β-TCP (206 vs. 318 days).</td>
<td>In a study of 109 single and multilevel PLIF spinal procedures, InQu demonstrated solid fusion in 94% of levels treated at 12 months. Mean time to fusion was 10 months.</td>
<td>Demonstrated clinically effective with excellent safety profile for broad applications, including nonunion, fracture fixation, Charcot reconstruction, and spinal fusion.</td>
</tr>
</tbody>
</table>
Newly woven bone forms over a long period of time

InQu + Autograft (no mineral component)

Cartilage ossifies & is remodeled to form bone

Mature woven bone after 9 months

Traditional synthetic graft (mineral component)

Graft breakdown triggers inflammation & may damage healthy tissue

Specialized cells respond & begin to digest minerals

Mineral deposits persist as new bone begins to form

MSCs differentiate & cartilage intermediate forms

Hyaluronic acid promotes MSC binding to InQu

Newly woven bone forms over a long period of time

InQu demonstrates robust fusion in challenging patient

“InQu Bone Graft Extender is a great choice for my fusions because it’s a cell-friendly scaffold that binds growth factors and accelerates robust bone formation”

- Christopher P. Silveri, M.D. Orthopedic Surgeon

Patient: 59-year-old female, BMI 39.3
Co-Morbidities: 23-year diabetic, previous smoker, hypertension & asthma
Treatment: L4/5 & L5/S1 TLIF with InQu
Outcome: solid fusion at 9 months, ODI score reduction from 84 to 50
Dr. Michael Steinmetz, Cleveland Clinic, OH
**SUPERIOR FUSION vs. β-TCP**

InQu demonstrated superior overall fusion rates by 12 months vs. β-TCP.

**InQu**

93%

**β-TCP**

68%

PERCENT OF TREATED LEVELS FUSED AT 12 MONTHS

INQU SUPPORTS RAPID BONE CONSOLIDATION AND IMPROVED RESORPTION COMPARED TO β-TCP

FUSION STUDIED SIDE-BY-SIDE IN 27 SUBJECTS

By 6 months:

1. **Greater volume of new bone** consolidation was observed for InQu-treated side.
2. **β-TCP** showed significant graft resorption and **limited bone formation**.

112 days faster

- Median time to fusion was 206 days for InQu vs. 318 days for β-TCP.
- InQu-treated levels emerged with statistically significant higher fusion grades compared to β-TCP by day 109.
ACHIEVE SUPERIOR FUSION WITH INQU

Proven Efficacy
Clinically proven fusion rates of 94%, outperforming fusion rates for ICBG at 12 months¹.

Faster Fusion
Shorter time to fusion vs. traditional synthetic bone grafts AND superior overall fusion rates at 12 months: 93% vs. 68%².

Use with Confidence
InQu offers a cost-effective, on-label solution for fusion throughout the spine.

Cell-Friendly
Integrated hyaluronic acid creates a cell-friendly microenvironment, binding MSCs and growth factors²,³.

Success in Complex Cases
Demonstrated robust fusion, even in challenging high-risk patients.

Exceptional Handling
A cohesive, moldable putty providing ease-of-use for a variety of applications.

EXCELLENT HANDLING IN THREE CONFIGURATIONS

InQu PASTE MIX PLUS
Cohesive putty available in 2.5cc, 5cc and 10cc sizes.

InQu MATRIX
Available as 5x5cm and 5x10cm moldable strips.

InQu GRANULES
Available in 30cc as a graft extender.

Schedule a case with your Isto sales representative or customer service at 888.705.ISTO.

References